Tumor gene expression analysis was performed by RNA sequencing in 823 patients from the IMmotion-151 trial, and differential outcomes based on T effector/IFNγ and angiogenesis gene expression signatures were demonstrated. The gene discussed is IFNG; the disease is neoplasm.